Kontakt Oss
Diagnostics
About Abbott
i-STAT-Registrering
i-STAT-Pålogging
Hjemmeside for kunder
Hjemmeside for partnere
Hjemmeside for ansatte
Min konto
COMPLETE PROFILE
DASHBOARD
Min konto
Norge

GLOBAL POINT OF CARE

Make Every Minute Count

Afinion CRP point of care testing helps to make the most of every consultation with the patient.

Rapid and accurate decision-making helps improve the quality of conversation between doctor and patient, facilitating more effective treatment discussions in minutes for pneumonia and other respiratory infections.

Contact Us
image
image

Make Every Consultation Count

Antimicrobial resistance is a serious healthcare and economic problem, which could affect our ability to defend ourselves from infectious disease. Viral respiratory tract infections (RTIs) are one of the most common reasons for unnecessary antibiotic prescribing by healthcare professionals (HCPs) and patient expectations place additional pressure to prescribe antibiotics, even when diagnosis is uncertain.1-3

Point-of-care CRP testing helps to make the most of every consultation with the patient. A collaborative assessment by EUnetHTA concluded that the use of CRP POCT leads to reduced antibiotic prescribing both at consultation and up to 28 days follow-up.4 CRP POCT facilitates effective communication with patients about self-management and antibiotic prescribing.5-7

CRP POCT can reduce antibiotic prescribing by up to 42%,1,4,8-14 combining CRP POCT with enhanced communication skills of GPs have been shown to result in an even higher relative reduction of > 60%.8,11

90% of RTIs are caused by a virus, meaning antibiotics are unlikely to have any clinical benefit for these patients.15 

Contact us for More information about our Afinion products

-

Clinical Confidence in Minutes

The Afinion CRP assay is a simple fingerstick test. Make every moment during the patient consultation matter by quickly and easily determining your patients’ CRP level.

  • From drop to decision in just 3 minutes
  • Easy-to-use all-in-one cartridge with no pre-analytical steps
  • Minimally invasive for the patient, 2.5 μL fingerstick sampling
  • Excellent agreement with laboratory methods13, 17-21
  • No user calibration necessary
Afinion CRP
Download Brochure
To find out more about how Afinion CRP can transform your consultations

Download our brochure and contact a member of our team today!

Download Brochure

To always find the latest information about the Point of Care Testing and get CPD | CME Accreditation, register at My POC Academy website using the link below:

mypocacademy

References

  1. Aabenhus et al. Cochrane Database of Systematic Reviews 2014;11:1-70.
  2. Stanton et al. Br J Gen Pract 2010;60(581):e466-75. 
  3. Longitude survey 2014: https://www.nesta.org.uk/press-release/benefit-of-the-doubt-is-the-basis-for-prescribing-antibiotics-finds-longitude-survey/. Downloaded Oct. 2021.
  4. O’Brien et al. EUnetHTA Project ID: OTCA012. 2019
  5. Wood F et al. Family Practice 2011; 28:661–669.
  6. Butler CC et al. Scandinavian Journal of Primary Health Care 2008; 26: 17-21.
  7. Huddy JR et al. BMJ Open 2016;6: e009959.
  8. Cals et al. BMJ 2009; 338(51):137.
  9. Cals et al. The Annals of Family Medicine 2010;8(2):124-133.
  10. Andreeva et al. BMC Family Practice 2014;15(1):80.
  11. Little et al. The Lancet 2013;382(9899):1175-1182
  12. Butler et al. N Engl J Med 2019;381(2):111-120.
  13. Verbakel et al. BMJ Open 2019;9:e025036.
  14. Cooke J et al. BMJ Open Resp Res 2020;7:e000624.
  15. Bjerrum et al. BioMed Central Family Practice 2010; 11:29.
  16. WHO. 18. Nov. 2020. Preventing the COVID-19 pandemic from causing an antibiotic resistance catastrophe. https://www.euro.who.int/en/health-topics/disease-prevention/antimicrobial-resistance/news/news/2020/11/preventing-the-covid-19-pandemic-from-causing-an-antibiotic-resistance-catastrophe
  17. Hughes A, et al. Clinical Pharmacist 2016 Oct.
  18. Ivaska L et al. PLOS ONE 2015;10(6):e0129920.
  19. Brouwer N, et al. Clin Chim Acta 2015; 15(439):195-201.
  20. Minnaard MC et al. Scand J Clin Lab Invest 2013;73(8):627-34.
  21. Bukve T, et al. Clin Chem 2016;62(11):1474-1481.
  22. Minnaard MC et al. Scandinavian Journal of Clinical& Laboratory Investigation 2015; 75: 291–295.
  23. CDC. 27. Oct. 2020. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease; 
  24. Luo et al. medRxiv preprint 2020; 
  25. Wang et al. Open Forum Infect Dis 2020; 
  26. Tan et al. ORCID iD: 0000-0002-2522-4524; 
  27. Li et al. Journal of Infection 2020; 
  28. Gao et al. J Med Virol 2020 ; 
  29. Guan et al. N Engl J Med 2020; 
  30. Zhu et al. ORCID iD: 0000-0001-7718-9591; 
  31. Chen et al. Lancet 2020; 
  32. Cao et al. medRxiv preprint 2020; 
  33. Zhang et al. Scandinavian J Clin Lab In 2020; 
  34. Dong et al. Int J Med Sci 2020; 
  35. Stringer et al. Int J Epidemi 2021; 
  36. Liu et al. J Clin Virol 2020; 
  37. Chen et al. Ann Clin Microbiol Antimicrob 2020; 
  38. Herold et al. J Allergy Clin Immunol 2020; 
  39. Dickens et al. Clinical Infectious Diseases 2020; 
  40. De Nardo et al. Int J Infect Dis 2020; 
  41. Feldt et al. STAKOB 2020; 
  42. Chinese National Health Commission. 3. March 2020. Chinese COVID-19 Management Guidelines; 
  43. Chinese Center for Disease Control and Prevention. 20. Aug. 2020. Treatment Strategies to Prevent Mild to Severe Progression of COVID-19 Cases; 
  44. SIMEU. 12. March 2020. Covid-19 First Line Report PS/DEA management organisational structure as part of an epidemic or pre-epidemic outbreak; 
  45. Regional Council of Campania Directorate General for the Protection of Health. Feb. 2020. Operational guidelines identification/management of suspected and proven cases of suspected Coronavirus; 
  46. IFCC. 6. April 2020. Information Guide on COVID-19

 

©2025 Abbott. Med enerett. Med mindre annet er angitt, er alle produkt- og tjenestenavn som vises på dette nettstedet, varemerker som eies av eller lisensieres til Abbott, dets datterselskaper eller partnere. Ingen av Abbott sine varemerker, handelsnavn eller kjennetegn på dette nettstedet kan brukes av andre uten forhåndsinnhentet skriftlig tillatelse fra Abbott, bortsett fra der de brukes for å identifisere produktet eller tjenesten til selskapet.

Dette nettstedet er regulert av gjeldende lover og statlige forskrifter i USA. Det kan hende at produktene og informasjonen som finnes her, ikke er tilgjengelig i alle land, og Abbott påtar seg ikke ansvar for informasjon som muligens ikke er i samsvar med juridiske prosesser, reguleringer, registrering og bruk i det enkelte land.

Din bruk av dette nettstedet og informasjonen som finnes her,  er underlagt nettstedets bruksvilkår og retningslinjer for personvern. Bildene som vises, er kun til illustrasjonsformål. Personer på bildene representerer ikke virkelige personer. Erklæring om personvernforordningen (GDPR).

Alle produkter er ikke tilgjengelige i alle regioner. For informasjon om tilgjengelighet i bestemte markeder kontakter du din lokale representant. Kun til bruk ved in vitro-diagnostikk. Ønsker du informasjon om i-STAT-testkassetter og tiltenkt bruk, kan du se de enkelte produktsidene eller informasjonen om kassetten (CTI/IFU) i delen for i-STAT-support.

Abbott – ledende innen pasientnær diagnostikk